Role of Montelukast in Asthma and Allergic rhinitis patients.

Abstract

OBJECTIVES:

Our objective was to evaluate the effect of Montelukast on the symptoms of asthma and allergic rhinitis (AR), assess its effect on the individual quality of life (QoL), and estimate the proportion of participants having adverse effects.

METHODS:

This prospective, open-label study conducted at Dow University of Health Sciences, Ankle Saria Hospital and Sindh Government Hospital Liaquatabad, Karachi, from August 2018 to September 2019, included patients aged >18 years with a clinical diagnosis of Asthma, AR, or both. Patients were given a 10 mg Montelukast tablet each day and then called for follow-up in the fourth week, where the questions related to the improvement in the symptoms of asthma or AR were asked. Patients were also asked about the improvement in QoL and any adverse effects.

RESULTS:

A total of 694 patients were registered of which 138(19.8%) had AR, 294(42.4%) had asthma, while 273(39.3%) had both. Mean age was 41.1±14.63 years and 352 (50.7%) were male and 342(49.3%) were females. On a follow-up visit, there was a sufficient improvement in 351 asthmatics (63.9%), and 288 patients with AR (70.1%) overall, strong or marked improvement in the day (n=342,62.3%) and night time (n=331,60.3%) asthma symptoms. Overall improvements in QoL were very good or good in 419 patients. Montelukast was well-tolerated here with adverse effects (like abdominal discomfort, fever, fatigue, headache, rash, and upper respiratory tract symptoms) seen in 125 patients (18.01%).

CONCLUSION:

Montelukast was very effective in improving the symptoms and QoL of the individuals suffering from asthma and/or AR.

• Authors: Faisal Faiyaz Zuberi, M Amir Haroon, Abdul Haseeb, Shafi Muhammad Khuhawar
• Journal: Pakistan journal of medical sciences (Pak J Med Sci) 2020 Nov-Dec Vol. 36 Issue 7 Pg. 1517-1522 ISSN: 1682-024X [Print] Pakistan
• PMID: 33235567 (Publication Type: Journal Article)
• Copyright: Copyright: © Pakistan Journal of Medical Sciences.